tbuckley/cabot-search huggingface dataset:
Feasibility study of capecitabine (cap) and cisplatin (cis) with radiation therapy (RT) in the management of patients with locally advanced unresectable squamous cell carcinoma of the head and neck (HNSCC)
Authors: J. W. Allen, S. Vasireddy, J. Kaufman, J. M. Hughes, M. Sebelik, J. E. Salazar, H. B. Niell
Journal: Journal of Clinical Oncology (2007)

16520 Background: Concurrent chemoradiation has become the standard of care for locally advanced unresectable HNSCC. The most commonly used chemotherapy is cis and 5-fluorouracil (5-FU). We evaluated the feasibility of using cap and cis during RT in this population. Cap is an oral pro-drug of 5-FU that can be given daily with RT in order to enhance the activity of RT. Methods: Between Oct, 2003 and Sept, 2005, 12 male patients aged 46–83 were treated at the VA Medical Center. Patients received cis 100 mg/m2 on days 1 and 29 and cap 450 mg/m2 bid (2 hours prior to RT and 12 hours later) for 5 days of each week concurrent with RT to a total dose of 70 Gy in 35 fractions over 7 weeks. Primary endpoint of the study was toxicity. Results: All 12 patients were able to complete therapy. Treatment delays and/or dose modifications were needed in 7 patients. Treatment related toxicities included 6 patients with grade 3 mucositis and 5 patients with grade 3 dysphagia. Other grade 3 toxicities included 3 patients with dehydration and 1 patient each with leucopenia, constipation, nausea and vomiting, and odynophagia. Percutaneous gastrostomy (PEG) tubes were required in 5 patients. Complete response to chemoradiation was seen in 9 patients, 2 patients obtained partial response, and 1 patient progressed. Median progression free and overall survivals have not been reached with a median follow-up of 21 months. Conclusions: Cis and cap administered concurrently with RT has manageable toxicities and is active in patients with locally advanced unresectable HNSCC. No significant financial relationships to disclose.
Abstract 2850: Morphological Variability: A New Electrocardiographic Technique for Risk Stratification After NSTEACS
Authors: Zeeshan Syed, Collin M Stultz, Benjamin M Scirica, Christopher P Cannon, Khaled Attia, Irina O Stebletsova, Satishkumar Mohanavelu, Peter H Stone, John V Guttag
Journal: Circulation (2007)

Background : ECG parameters such as low heart rate variability (HRV) identify patients at high risk post-ACS. We recently developed morphological variability (MV), a novel technique that quantifies differences in the morphology of entire beats using a dynamic time-warping algorithm. MV incorporates strictly more information than HRV, potentially offering a more complete evaluation of the ECG. We assessed the relationship among MV, HRV, and outcomes after NSTEACS. Methods: MV and HRV were calculated in 863 pts from the DISPERSE2 trial using the first 24 hrs of continuous ECG (CECG) after randomization for NSTEACS. Using each measure, pts were split into high and low variability groups (cutpoint for HRV (SDNN)= 75ms and for MV=0.7). Ischemia on CECG was defined as ≥1mm ST dep lasting ≥1min. Results: A total of 144 (16.7%) pts had high MV and 58 (6.7%) had low HRV. Pts with high MV experienced higher rates of death, death/MI/severe recurrent ischemia (SRI), and ischemia detected on CECG compared to low MV. (Table-Figure ) This relationship remained consistent in pts with no ischemia on CECG (hazard ratio for D/MI/SRI =2.5, p=0.016). There was no difference in mortality or ischemia on CECG in pts with low HRV v high HRV, but pts with low HRV did have higher rates of death/MI/SRI. (Table) Conclusions: MV correlates significantly with poor cardiovascular outcomes, including death, after NSTEACS, even after controlling for other high risk features and even among pts without electrocardiographic evidence of ischemia. MV may offer a new non-invasive measure for risk stratification after ACS.
A NEW OBSERVATION HELPFUL IN THE DIAGNOSIS OF CORONARY THROMBOSIS
Authors: Peter J. Steincrohn
Journal: Annals of Internal Medicine (1940)

Article1 September 1940A NEW OBSERVATION HELPFUL IN THE DIAGNOSIS OF CORONARY THROMBOSISPETER J. STEINCROHN, M.D.PETER J. STEINCROHN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-14-3-495 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe various descriptions of coronary thrombosis pain in the literature may be summarized as follows: The pain results from anoxemia of the cardiac musculature secondary to decreased blood supply; it is intense, unbearable, and amenable only to large doses of morphine; its location is usually under the lower sternum or in the epigastric region; the pain may be referred, among other locations, to the arms or jaw; the pain is continuous and is accompanied by varying degrees of shock.In studying patients during attacks of coronary thrombosis, I have observed a pain syndrome which has not been mentioned or stressed... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: PETER J. STEINCROHN, M.D.Affiliations: Hartford, Connecticut*Received for publication December 12, 1938. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie Coronarerkrankungen. Coronarinsuffizienz, Angina pectoris und HerzinfarktTHE INITIAL ATTACK OF ACUTE MYOCARDIAL INFARCTION*THOMAS P. JACOBS, M.D. 1 September 1940Volume 14, Issue 3 Page: 495-501 Keywords Blood Hypoxia Morphine Shock Sternum Thrombosis ePublished: 1 December 2008 Issue Published: 1 September 1940 PDF downloadLoading ...
Abstract 14868: Cardiovascular Magnetic Resonance Imaging Based Detection of Chronic Iron Deposition within Non-Reperfused Myocardial Infarctions
Authors: Avinash Kali, Ivan Cokic, Hsin J Yang, Richard L Tang, Rohan Dharmakumar
Journal: Circulation (2014)

Introduction:  Chronic iron deposition is known to occur in reperfused hemorrhagic myocardial infarctions (MIs), and could potentially mediate prolonged inflammatory activity and electrical anomalies in the heart.   Hypothesis:  We investigated whether stagnant blood in permanently ligated vasculature of non-reperfused MIs could also potentially lead to chronic iron deposition within infarcted territories.   Methods:  Canines (n=19) underwent permanent ligation of LAD. CMR exams were performed at 7 days and 4 months post-MI at 3T, and T2* maps and Late Gadolinium Enhancement (LGE) images were acquired. Infarcted territories were detected on LGE images using Mean + 5 Standard Deviations criterion relative to a reference region-of-interest placed in the remote myocardium. Presence of iron within MI territories was detected on T2*-weighted images using Mean - 2 Standard Deviations criterion relative to a reference region-of-interest placed in the remote myocardium. Following the month 4 CMR study, animals were euthanized and ex-vivo histology was performed.   Results:  Significant T2* losses were observed within the MI territories in 13 of the 19 canines at 7 days post-MI, and in all canines at 4 months post-MI. Relative to remote myocardium, mean T2* value of the hypointense cores within MI territories was 42.6±10.5% lower on day 7 post-MI (16.7±3.4ms vs. 28.8±3.0ms, p   Conclusions:  Chronic iron depositions can occur within non-reperfused MIs. The long-term effect of such iron depositions remain to be investigated.
Adjuvant Chemotherapy Followed by Goserelin Versus Either Modality Alone for Premenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial
Authors: Monica Castiglione-Gertsch, Anne O'Neill, Karen N Price, Aron Goldhirsch, Alan S Coates, Marco Colleoni, M Laura Nasi, Marco Bonetti, Richard D Gelber
Journal: JNCI Journal of the National Cancer Institute (2003)

Background: Although chemotherapy and ovarian function suppression are both effective adjuvant therapies for patients with early-stage breast cancer, little is known of the efficacy of their sequential combination. In an International Breast Cancer Study Group (IBCSG) randomized clinical trial (Trial VIII) for pre- and perimenopausal women with lymph node–negative breast cancer, we compared sequential chemotherapy followed by the gonadotropin-releasing hormone agonist goserelin with each modality alone. Methods: From March 1990 through October 1999, 1063 patients stratified by estrogen receptor (ER) status and radiotherapy plan were randomly assigned to receive goserelin for 24 months (n = 346), six courses of "classical" CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360), or six courses of classical CMF followed by 18 months of goserelin (CMF → goserelin; n = 357). A fourth arm (no adjuvant treatment) with 46 patients was discontinued in 1992. Tumors were classified as ER-negative (30%), ER-positive (68%), or ER status unknown (3%). Twenty percent of patients were aged 39 years or younger. The median follow-up was 7 years. The primary outcome was disease-free survival (DFS). Results: Patients with ER-negative tumors achieved better disease-free survival if they received CMF (5-year DFS for CMF = 84%, 95% confidence interval [CI] = 77% to 91%; 5-year DFS for CMF → goserelin = 88%, 95% CI = 82% to 94%) than if they received goserelin alone (5-year DFS = 73%, 95% CI = 64% to 81%). By contrast, for patients with ER-positive disease, chemotherapy alone and goserelin alone provided similar outcomes (5-year DFS for both treatment groups = 81%, 95% CI = 76% to 87%), whereas sequential therapy (5-year DFS = 86%, 95% CI = 82% to 91%) provided a statistically nonsignificant improvement compared with either modality alone, primarily because of the results among younger women. Conclusions: Premenopausal women with ER-negative (i.e., endocrine nonresponsive), lymph node–negative breast cancer should receive adjuvant chemotherapy. For patients with ER-positive (i.e., endocrine responsive) disease, the combination of chemotherapy with ovarian function suppression or other endocrine agents, and the use of endocrine therapy alone should be studied.
322. Characterization of IFNγ Gene Expressions in Rat Tissues with Real Time Quantitative RT-PCR
Authors: Baohong Tian, Sarah S. Rentz, Gregory S. Gorman, Rogers Tina, John G. Page
Journal: Molecular Therapy (2004)

As a regulatory protein, IFNγ plays a pivotal role in the immune system by modulating the immune responses, including lymphocyte activation, survival, and apoptosis. Therefore it is essential to gain insight into the immune processes by studying the gene expression patterns in tissues. Due to its low abundance, the gene expressions of IFNγ were very difficult to quantitate at the levels expressed in tissues until the development of real time PCR technology. This study was designed to characterize the gene expression patterns of IFNγ in a variety of tissues using real time quantitative RT-PCR (Q-RT-PCR). In order to obtain accurate and reproducible results, the tissue amount used for RNA isolation was optimized for each tissue type and Q-RT-PCR assays were developed and validated.
Organ preservation using carboplatin, capecitabine, docetaxel, and radiotherapy in head and neck cancer: A phase II study.
Authors: D. F. Saragiotto, F. C. Maluf, L. G. Brandão, F. F. de Arruda, F. Costa, J. Luis, S. S. Arap, P. Michaluart, S. C. Martins
Journal: Journal of Clinical Oncology (2010)

5571 Background: Induction chemotherapy (ICT) with a fluoropyrimidine, platinum and taxane combination followed by radiation therapy or concurrent chemoradiation (CRT) has become a new standard of care in locoregionally advanced, unresectable head and neck squamous cell carcinoma (SCC). The use of the same combination of three-drug therapy in ICT and CRT has not been adequalely tested for organ preservation. Methods: In this phase II study, patients (pts) who had biopsy-proven stage III or IV SCC and no distant metastasis, PS 0 or 1, good organ function and no prior chemotherapy or radiation received two cycles of chemotherapy (CT) with i.v. docetaxel 70 mg/m2 on day 1 plus i.v. carboplatin AUC 5 on day 1 plus capecitabine 1g/m2 orally daily b.i.d every 28 days. Patients with disease progression or stable disease were excluded. Responding pts received two more cycles of the same CT concurrent with concomitant boost radiation therapy (72 Gy). Results: Twenty-five pts were enrolled: 15 oropharynx, 8 larynx and 2 hypopharynx. Stage distribution was: III (24%), IVA (72%) and IVB (4%). All pts completed the ICT and CRT, and 96% received the planned four cycles of CT. The response rate was 88% and only one patient had progression after 3 months of treatment completion. Grade 3/4 neutropenia occurred in 20% and 56% of pts during ICT and CRT, respectively. During CRT, the rate of grade 3 febrile neutropenia was 36% and grade 3/4 mucositis was 72%. One patient died during treatment as a result of a ruptured aortic aneurysm. After a median follow-up of 4.6 years only one patient died as a result of metastatic disease. The median survival had not been reached. Neither tracheotomy, nor feeding tubes, were needed 6 months after finishing CRT. Conclusions: Three-drug induction therapy with docetaxel, carboplatin and capecitabine 1g/m2 followed by concurrent by the same agents and concomitant boost radiation therapy is feasible and very promising in a selected head and neck patient population, with high response and organ preservation rates. No significant financial relationships to disclose.
Controversy in primary care: Should asymptomatic haemochromatosis be treated? Treatment can be onerous for patient and doctor Commentary: False certainty of clinical guidance Commentary: Early treatment is essential
Authors: C. J Seamark
Journal: BMJ (2000)

Controversy in primary care Should asymptomatic haemochromatosis be treated?Genetic testing now allows haemochromatosis to be diagnosed before symptoms emerge.Testing is potentially beneficial because early treatment of iron overload is the only way to prevent organ damage.Treatment by venesection is, however, lengthy and can have a detrimental effect on quality of life, and not all patients with the mutation will develop symptoms.A general practitioner and her patient describe their experience of treatment of asymptomatic haemochromatosis and ask whether it was really necessary.Their experiences are commented on by a general practitioner and a consultant haematologist.
Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy
Authors: Brad H. Rovin, Yuxiao Tang, Junfeng Sun, Haikady N. Nagaraja, Kevin V. Hackshaw, Linda Gray, Robert Rice, Daniel J. Birmingham, Chack-Yung Yu, Dan N. Spetie, Amy Aziz, Lee A. Hebert
Journal: Kidney International (2005)
A single high‐resolution <scp>HLA</scp> mismatch has a similar adverse impact on the outcome of related hematopoietic stem cell transplantation as a single low‐resolution <scp>HLA</scp> mismatch
Authors: Shigeo Fuji, Junya Kanda, Shunichi Kato, Kazuhiro Ikegame, Satoko Morishima, Toshihiro Miyamoto, Michihiro Hidaka, Kohmei Kubo, Koichi Miyamura, Mitsuru Tsudo, Hikaru Kobayashi, Yoshitomo Maesako, Tetsuya Eto, Souichi Adachi, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshinobu Kanda
Journal: American Journal of Hematology (2015)

The relative importance of the resolution level of HLA typing has not been fully defined for related donor transplantation. To address this question, we retrospectively evaluated patients who underwent a first related hematopoietic stem cell transplantation (HSCT) from 2000 to 2011 from an HLA high-resolution matched (MRD, n = 2,244), high-resolution 1 locus-mismatched (HR-MMRD, n = 116), or low-resolution 1 locus-mismatched related donor (LR-MMRD, n = 396) in the graft-versus-host direction at three loci (HLA A, B, and DRB1) using the database of the Japan Society for Hematopoietic Cell Transplantation. The median age was 40 years (0-74). The median follow-up duration of surviving patients was 950 days. Although the cumulative incidences of grade III-IV acute graft-versus-host disease (GVHD) in the HR-MMRD and LR-MMRD groups were significantly higher than those in the MRD group (HR-MMRD 19.8%, LR-MMRD 20.4%, and MRD 9.5%), there was no statistically significant difference between the HR-MMRD and LR-MMRD groups (P = 0.65). Although both HR-MMRD and LR-MMRD were significantly associated with an increased risk of non-relapse mortality and a worse overall survival, there was no statistically significant difference between the HR-MMRD and LR-MMRD groups. In conclusion, LR-MM and HR-MM have a similar adverse impact on the outcome in related HSCT.
The end of triglycerides in cardiovascular risk assessment?
Authors: N. Sattar, C. J Packard, J. R Petrie
Journal: BMJ (1998)

Although serum triglyceride concentrations are often measured in clinical practice, Garber and Avins1plausibly argued in the BMJ in 1994 that their use in screening for cardiovascular risk was “experimental.” In particular, they argued that there was no evidence that triglycerides values identified those who benefited from further evaluation or treatment and that there was more evidence for measuring high density lipoprotein cholesterol concentrations. Since then the importance of low density lipoprotein cholesterol has been emphasised by landmark trials of statins (WOSCOPS, 4S) in the primary and secondary prevention of coronary heart disease, and cheaper and simpler” direct“ assays have emerged for high density lipoprotein cholesterol. Both these events might have been expected to hasten the demise of triglycerides—but clinicians continue to request triglyceride assays together with measurements of total cholesterol in patients at risk of cardiovascular disease.

Garber and Avins conceded the biological plausibility of a causal role for triglycerides in coronary heart disease but argued that an association (causal or otherwise) had never been proved. They highlighted the biological variability in fasting serum triglyceride concentrations …
Human Developmental Genetics.
Authors: David Yi-yung Hsia
Journal: Annals of Internal Medicine (1969)

This monograph contains 197 pages with 217 references. It consists of four parts. The first is an introduction which gives a clear discussion of the nomenclature of the globulins, M-componentparaproteins, and the clinical importance of monoclonal vs polyclonal hypergammaglobulinemias. Eight pages are devoted to the diagnostic importance of the erythrocyte sedimentation rate. The second part contains a discussion of the monoclonal hypergammaglobulinemias. This includes the incidence of reticuloendothelial malignancies associated with monoclonal globulinopathies, metabolic derangements associated with multiple myeloma, characterization and significances of the cryoglobulins, euglobulins, and cold agglutinins. Eleven pages are devoted to the differentiation between monoclonal essential hypergammaglobulinemia and myeloma. The discussion concerning the concepts of homogeneous monoclonal and biclonal globulin production appeared confusing. The third portion of the monograph is devoted to the polyclonal hypergammaglobulinemias. In this section, Waldenstrom discusses the relationship of autoimmune diseases to polyclonal hyperglobulinemias, serological effects of polyclonal hyperglobulinemia, the relationship between collagen and autoim¬ mune disease, purpura hyperglobulinemia, circulating anticoagulants (as related to disturbances in globulin formation), sarcoid-like granuloma in relationship to autoimmunity, and polyclonal increase in -globulins. The fourth portion of the mono¬ graph contains a general discussion concerning monoclonal and poly¬ clonal increases in -globulins. This monograph is well written. The only criticism is the absence of good statistical data concerning the incidence of various abnormal para¬ meters discussed. Much of the text is devoted to Waldenstrom's testimonial of his own personal experience and theories rather than a review and organization of the existing informa¬ tion on this subject. I can recommend this monograph to medical students and any physician who is interested in gaining an understanding of cur¬ rent concepts of abnormal proteins. John Louis, MD Hines, Ill
The attitude of patients suffering from COPD towards addiction to smoking and attempts to smoking cessation
Authors: Piotr Kuna, Izabela Kuprys-Lipinska
Journal: European Respiratory Journal (2014)

In 2012 the nationwide survey of COPD subjects was conducted in Poland.The aim of this analysis is to evaluate the attitude of patients suffering from COPD towards addiction to smoking with particular attention to the effort of smoking cessation.Data were collected from patients by their physicians during routine visits based on a uniform questionnaire.The study involved 10,365 outpatients (>35yrs of age, with COPD, current/ex-smokers).Representative sample of 2,967 questionnaires were randomly drawn for the statistical analysis.The mean age of patients was 61.15±10.25yrs, 33.98% were women and 56.73%–current smokers.As patients reported, addiction–28.44% and pleasure–23,34% were the main reasons of smoking.Willingness of smoking cessation was declared by 69.62% of smokers.Its main reason was COPD diagnosis–35.06% and worry about health–26.58%.Only 39.36% of smokers were persuaded by physicians to smoking cessation at every visit and 49.56% received an advice how to do it.54.03% of current smokers had made attempts to quit smoking with no persistent effect.Unsuccessful attempts were excused mainly by habituation–25.08%.Effective smoking cessation applies to men aged >60yrs, pensioners with COPD grade C/D and comorbidities, who smoke >20 cigarettes/day from >30yrs (≥30 pack-years) due to addiction,habits or smoking friends.Ineffective quitting smoking affects women under  Study funded by Polpharma .
In vitro modeling of lymph node metastasis in breast cancer.
Authors: Lenaic Paon, Sue A. Eccles
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

5154 

Lymph node metastasis is a common feature of many cancers. It is associated with considerable morbidity and is often linked to poor prognosis. As part as the European Framework 6 Consortium METABRE, we used the parental cell line MDA-MB-435 and two metastatic sublines, LN1 and LV1, derived from lymph node and liver metastases respectively, as a model to study organ-specific metastasis and to compare the mechanisms of lymphatic and hematogenous metastasis. When injected into mammary fat pads of athymic mice, LN1 (but not LV1) produced spontaneous lymph nodes metastases, whereas when injected intravenously all three lines generated experimental lymph node metastases as well as lung metastases. These distinct patterns of spread - due respectively to direct (intralymphatic) and indirect (hematogenous) colonisation of nodes - will enable us to explore determinants of both mechanisms independently. In an attempt to study the mechanism of lymph node metastasis in vitro , we initially compared the migration and invasion potential of these cell lines in Transwell® assays under different conditions. The filter inserts were either uncoated or coated with collagen IV, and the lower chamber contained either standard culture medium supplemented with 5% FCS, lymphatic endothelial cells (LECs) or LEC-conditioned medium. MDA-MB-435 parental cells and LV1 in all cases migrated more readily than LN1, suggesting that under these conditions, we were unable to detect any organotropism due to the presence of LECs or secreted products. We are now exploring 3D models in which fluorescently tagged tumour cells are co-cultured with Matrigel® supplemented with fibroblasts above a layer of LECs, in order better to mimic the in vivo environment. Additionally, future studies will compare spontaneous and experimental lymph node metastasis from MDA-MB-435 cell lines and a second model (GI 101 and sublines) using gene expression microarrays, in order to explore the potential different mechanisms involved in these two routes of dissemination.